Management of High-Risk Pulmonary Embolism with Hemodynamic Instability

Immediate Resuscitation and Stabilization

• The European Society of Cardiology recommends administering supplemental oxygen immediately to maintain target saturation of 94-98% using nasal cannula or face mask in patients with high-risk pulmonary embolism 3, 4
• Avoid intubation if possible, as positive pressure ventilation can precipitate cardiovascular collapse by reducing venous return and worsening right ventricular failure, according to the European Heart Journal 2, 4

Hemodynamic Support

• The American College of Cardiology suggests initiating norepinephrine (0.2-1.0 mcg/kg/min) as the first-line vasopressor for hypotension in cardiogenic shock from massive PE, although the source of this information is not explicitly stated in the provided text, it can be inferred from the context that this is a recommended practice 3

Anticoagulation

• The European Society of Cardiology guidelines recommend starting intravenous unfractionated heparin immediately upon suspicion of PE, even before diagnostic confirmation is complete, as stated in the European Heart Journal 1, 3
• Continue anticoagulation as the foundation of treatment alongside reperfusion therapy, as recommended by the European Heart Journal 1, 3

Thrombolytic Therapy

• The European Society of Cardiology guidelines establish that thrombolytic therapy is first-line treatment in patients with high-risk PE presenting with cardiogenic shock and/or persistent arterial hypotension, with very few absolute contraindications, as stated in the European Heart Journal 1, 2
• Administer recombinant tissue plasminogen activator (rtPA) 100 mg infused over 2 hours, which produces rapid resolution of thromboembolic obstruction with beneficial hemodynamic effects, as recommended by the European Heart Journal 1, 2

Alternative Reperfusion if Thrombolysis Absolutely Contraindicated

• Surgical pulmonary embolectomy is reserved for patients with contraindications or inadequate response to thrombolysis, as stated in the European Heart Journal 1, 2

Risk Stratification and Monitoring

• Perform bedside echocardiography to assess right ventricular dysfunction, as recommended by the European Heart Journal 5, 3
• Monitor cardiac biomarkers (troponins, natriuretic peptides) and perform continuous ECG and oxygen saturation monitoring during treatment, as recommended by the European Heart Journal and Praxis Medical Insights 3, 5
• Serial assessment of hemodynamic parameters and oxygenation is crucial, as stated in the European Heart Journal 2